Skip to main content
Fig. 3 | Critical Care

Fig. 3

From: Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial

Fig. 3

Effect of statin pre-treatment on monocyte-derived macrophage inflammasome activation. Monocyte-derived macrophages were pre-treated with either 50 µM simvastatin or 50 µM rosuvastatin for 4 h before stimulation with 100 ng/ml LPS and 2 mM ATP. In contrast to rosuvastatin, simvastatin significantly reduced the production of both (A) IL-18 and (B) IL-1β by MDMs (p < 0.05). When compared to the unstimulated control, rosuvastatin pre-treatment was associated with significantly higher IL-1β production (p < 0.05). Data analysed using Kruskal–Wallis test with Dunn’s multiple comparison test for between group differences. * = p < 0.05. N = 6 for all groups

Back to article page

Critical Care

ISSN: 1364-8535